Health Canada Clears Bemotrizinol (PARSOL Shield) for Multifunctional Skincare and Cosmetics — What Brands and Formulators Need to Know

Table of Contents

1. Key Highlights
2. Introduction
3. What Health Canada changed and why it matters
4. Bemotrizinol’s profile: why formulators are excited
5. The science that underpinned Health Canada’s decision
6. How the Canadian move affects the U.S. and global regulatory landscape
7. Practical product development advantages: the "global chassis" approach
8. Opportunities across categories: where bemotrizinol will drive new launches
9. Technical considerations for formulators
10. Claims, labeling and regulatory practice: what brands must consider
11. Risks, unknowns and quality control
12. Business implications and market outlook
13. Steps brands and formulators should take now
14. What the updated monograph suggests about future regulatory trends
15. Final considerations for marketers and consumer-facing teams
16. FAQ

Key Highlights

• Health Canada added bemotrizinol (PARSOL Shield) to the Secondary Sunscreen Monograph, allowing its use in multifunctional topical products (including daily skincare and color cosmetics) at concentrations up to 6%.
• The decision rests on extensive safety, absorption, clinical and long-term performance data; it aligns Canada more closely with other major markets and strengthens the regulatory case for U.S. approval.
• Broader approval simplifies global formulation strategies, enables lighter, non-whitening SPF solutions for hybrids and makeup, and can accelerate cross-market product launches — but it also introduces labeling and testing decisions brands must navigate carefully.

Introduction

Health Canada’s February 27, 2026 update to the sunscreen monographs marks a practical pivot for formulators and brands: bemotrizinol, marketed as PARSOL Shield, is no longer confined to products expressly regulated as sunscreens. The filter’s addition to Canada’s Secondary Sunscreen Monograph allows its inclusion in multifunctional topical formulations where sun protection is a secondary benefit. That regulatory shift opens immediate technical and commercial opportunities for daily skincare, color cosmetics, and hybrid products while tightening the global regulatory trajectory for this widely used UV filter.

The decision reflects a substantial evidentiary base—nonclinical, clinical, dermal absorption and long-term safety studies—and follows a long record of international use. For product developers, the change reduces regional formulation friction, supports leaner filter systems, and makes anti-UV technology more accessible within everyday beauty formats. For consumers, the practical effect could be more wearable sun protection baked into items people already use every day. The operational details, however, matter: concentration limits, claimability, testing regimes, and cross-border regulatory nuances will determine how quickly brands can translate this permission into market-ready products.

The sections that follow lay out what exactly changed in Canada, why bemotrizinol matters technically and commercially, how the decision interacts with the ongoing U.S. review, and the steps formulators and brand teams should take to leverage the new allowance while meeting safety, labeling and performance expectations.

What Health Canada changed and why it matters

Health Canada amended its sunscreen monograph framework to include bemotrizinol (PARSOL Shield) in the Secondary Sunscreen Monograph. Previously, the filter’s use in Canada was limited to products governed by the Primary Sunscreen Monograph—essentially formulations whose principal purpose is sun protection. The Secondary Monograph permits the ingredient’s use in products where sun protection is not the primary function: for example, a daily moisturizer, tinted serum, or foundation that delivers incidental but meaningful UV defense.

One practical outcome of the revision is an explicit concentration allowance: bemotrizinol may be used up to 6% in these multifunctional formulations. The update also removed a footnote tied to an earlier table in the monograph that had constrained formulation parameters, increasing design flexibility for formulators. According to industry scientists, this expands the types of textures and delivery systems that can effectively include the filter.

That flexibility translates to two immediate advantages. First, formulators gain access to a highly photostable, broad-spectrum filter that delivers UVA and UVB coverage at relatively low concentrations, helping keep textures light and finishes non-whitening. Second, brands get a regulatory pathway to include substantive sun protection in products that do not carry a primary sunscreen claim, reducing the need to create and market distinct sunscreen SKUs for every product family.

Bemotrizinol’s profile: why formulators are excited

Bemotrizinol has several properties that make it attractive in modern UV protection systems:

• Photostability: Unlike some organic filters that degrade under UV exposure, bemotrizinol resists photodegradation. That stability helps maintain SPF and UVA protection over time and reduces the need for frequent reapplication due to filter breakdown.
• Broad-spectrum efficacy at low concentrations: The molecule contributes to both UVB and UVA protection efficiently at modest loading levels, which supports sheer formulations with minimal whitening.
• Compatibility: Bemotrizinol mixes well with both organic and inorganic filters and with many oils and active ingredients, enabling combinations with antioxidants, barrier lipids, and treatment actives without destabilizing the formula.
• Formulation aesthetics: Its performance supports elegant textures—silky serums, fluid moisturizers, lightweight foundations—that meet contemporary consumer expectations for non-greasy, non-whitening finishes.

These characteristics make bemotrizinol a natural choice when the design brief calls for everyday protective products that consumers will actually wear. Tinted moisturizers, BB/CC creams, foundations intended to preserve shade integrity, and hybrid skincare-SPF serums are direct beneficiaries of a filter that preserves color and clarity while delivering measurable UV defense.

The science that underpinned Health Canada’s decision

Health Canada’s decision leaned on a substantial dossier of safety and performance evidence. Bemotrizinol has a long global track record, spanning more than two decades of use in markets outside North America. The dossier reviewed by regulators included:

• Nonclinical toxicology: Animal and cellular studies addressing acute and chronic exposure, irritation and sensitization, genotoxicity, and systemic toxicity.
• Dermal absorption and pharmacokinetics: Studies quantifying percutaneous absorption and systemic exposure under realistic use conditions, demonstrating low systemic availability when applied topically at intended concentrations and frequencies.
• Clinical data: Human trials assessing irritation, sensitization, photostability in-use, and efficacy endpoints including SPF and UVA protection.
• Long-term safety assessments: Post-market surveillance information and targeted long-duration studies addressing cumulative exposure.

Health Canada’s acceptance reflects the consistency and completeness of these datasets. Regulators interpreted the totality of evidence as comparable to the safety and efficacy data under review by the U.S. Food and Drug Administration. That convergent science strengthens bemotrizinol’s standing across major authorities and supports its inclusion not only where sunscreen is the primary function, but also where it is secondary.

How the Canadian move affects the U.S. and global regulatory landscape

The Canadian update arrives amid continuing U.S. deliberation. Bemotrizinol is currently under review by the FDA for potential inclusion in the OTC Sunscreen Monograph. Industry expects a final order as part of the FDA’s Tier 1 Over-the-Counter Monograph (OMOR) process; sources indicate a possible final order by June 2026, with the rule taking effect 60 days thereafter.

When a major regulator like Health Canada expands authorized use, it has both scientific and strategic ripple effects. Scientifically, it confirms the same safety and performance endpoints being evaluated by the FDA. Strategically, it creates positive momentum for manufacturers seeking synchronized global launches. Regulators in Europe, Asia and Australia have long allowed bemotrizinol, and Canadian alignment moves the North American regulatory environment closer to that international consensus. The cumulative effect is reduced friction for multinational brands and a stronger argument for the U.S. regulator to consider similar allowances.

Still, regulatory alignment is not a single switch. Differences in permissible claims, labeling rules, testing requirements and enforcement practices remain. Companies seeking to sell the same formulation across regions must still design for the narrowest regulatory lane applicable or make low-cost regional tweaks to meet divergent rules.

Practical product development advantages: the "global chassis" approach

For cross-border launches, the most tangible benefit comes from simplification. Brands can design a single core formulation—a "global chassis"—that meets safety and performance goals and then make minimal regional adjustments for claims or labeling.

Key efficiencies:

• Reduced duplicate testing: When major regulators accept the same active, companies can often leverage shared safety and efficacy datasets instead of repeating redundant studies for each market.
• Faster time-to-market: Regulatory acceptance in additional jurisdictions shortens the timeline to prepare and certify regional dossiers, which shortens the launch calendar for products intended for several markets.
• Streamlined supply chain: A consistent core formula reduces the need for parallel inventory streams and allows centralized manufacturing.
• Consistent consumer experience: The same texture, shade range, and performance profiles can be offered across regions, strengthening brand equity.

If the FDA finalizes an allowance up to 6% through the OMOR process, a single formulation designed for that ceiling could qualify for both U.S. and Canadian markets with minimal adaptation. That possibility makes bemotrizinol particularly attractive to global brands juggling regulatory divergence.

Opportunities across categories: where bemotrizinol will drive new launches

The Secondary Sunscreen Monograph permission opens clear opportunities across categories that traditionally struggle to deliver credible SPF without compromising aesthetics.

Daily-wear skincare Lightweight creams, morning serums, and moisturizers can incorporate bemotrizinol to provide measurable incidental protection. Consumers often skip dedicated sunscreens; embedding robust filters into products already used every morning increases the chance of consistent protection. Because bemotrizinol performs at low loading, formulators can maintain elegant finishes and avoid tackiness.

Color cosmetics Tinted moisturizers, foundations, BB/CC creams, and concealers frequently suffer from white cast and shade shifting when paired with mineral sunscreens like zinc oxide and titanium dioxide. Bemotrizinol’s shear efficacy and compatibility support sheer, non-whitening finishes, preserving shade integrity—especially in deeper tones—while delivering UV defense. That helps brands targeting inclusivity and shade fidelity.

Hybrid and multifunctional products Barrier-boosting lotions with antioxidants, anti-aging serums with SPF support, and lip and eye treatments with incidental protection become easier to formulate. Compatibility with oils and actives allows brands to reduce SKU proliferation—one product can deliver treatment benefits plus trusted UV defense.

Suncare alternatives and personal care Products not marketed as sunscreens but sold in categories such as facial oils, BB creams, and daily mists can now incorporate bemotrizinol without automatically converting to a primary sunscreen SKU. That flexibility helps companies experiment with new formats like powder SPF toppers, makeup primers with built-in UV filters, and sprays designed for on-the-go touch-ups.

Real-world example scenarios

• A premium moisturizer marketed for daily antioxidant protection adds bemotrizinol and gains a measurable SPF of 15–20 in lab testing while retaining its original feel and shine control. The brand positions the product as a "defense moisturizer" rather than a sunscreen to keep packaging consistent with its skincare positioning, while meeting secondary monograph rules.
• A foundation line reformulates to include bemotrizinol at 3–4%, enabling SPF 15–30 performance without whitening. Shade matching remains consistent across the range, helping the brand avoid multiple shade adjustments and consumer complaints about cast.
• A hybrid BB-serum combines niacinamide, peptides and bemotrizinol to deliver everyday defense and treatment in a single SKU, replacing separate treatment and SPF products in a consumer’s routine.

Technical considerations for formulators

Bemotrizinol’s favorable profile simplifies many formulation challenges but does not eliminate them. Developers must address specific technical and stability concerns, and adapt development workflows accordingly.

Concentration and efficacy While effective at modest levels, bemotrizinol’s inclusion must be calculated within the system of other filters to meet targeted SPF and UVA requirements. Formulators should evaluate critical wavelength, UVA-PF, and in vivo/in vitro SPF test results for each proposed formula. Synergistic pairings—combining bemotrizinol with other filters that complement its spectral coverage—enable leaner overall filter loads.

Photostability testing Although bemotrizinol offers high photostability, formulation matrices, dosages and co-ingredients can affect real-world performance. Conduct photostability assessments on finished products under realistic usage and irradiation conditions. Repeated exposure and reapplication simulations help verify performance retention.

Compatibility with pigments and pigments’ effect on appearance Pigmented products introduce interactions that affect both UV protection and appearance. Organic filters can influence tone and opacity when paired with pigments; bemotrizinol’s low whitening tendency helps preserve shade fidelity, but formulators should conduct shade stability, melt point, and dispersibility tests across the entire color range.

Interactions with actives and oils Bemotrizinol blends with many oils and actives, but certain reactive ingredients and high-solvent carriers may modify its behavior. Antioxidants, retinoids, and certain peptides require compatibility testing to confirm stability and to rule out unexpected chemical interactions or color changes.

Emulsion design and rheology Achieving the right sensory profile demands attention to emulsion architecture. Bemotrizinol’s solubility characteristics influence oil phase selection and emulsifier systems. Microemulsions, polymorphic emulsions, and silicone-based textures each present trade-offs among feel, spreadability and filter solubilization.

Inorganic filter synergy Combining bemotrizinol with zinc oxide or titanium dioxide can deliver robust UVA and UVB coverage while minimizing whitening. Particle size, coating material, and dispersion methods for inorganic filters influence the final aesthetic and MUST be optimized in tandem with organic filters.

Manufacturing controls Filter loading accuracy, homogenization energy, and process temperatures affect distribution and ultimate efficacy. Scale-up trials should reproduce the mixing and heat history of lab batches to verify that SPF and UVA profiles remain consistent at production volumes.

Shelf-life and storage Stability studies under ICH conditions and real-time shelf-life testing will confirm long-term performance. Assess UV filter degradation, rheology shifts, microbial stability, and pigment migration over 12–24 months to validate label claims.

Claims, labeling and regulatory practice: what brands must consider

The regulatory mechanics determine not only formulation feasibility but also what claims brands can truthfully and legally make on-pack and in marketing.

Primary vs. secondary claims If a product is marketed primarily as a sunscreen and bears explicit SPF or sun protection claims, it must meet the Primary Sunscreen Monograph requirements, including specific testing and labeling. If sun protection is incidental and not the product’s primary claim, the Secondary Sunscreen Monograph permits bemotrizinol’s inclusion but imposes limits on concentration and possibly on the nature of claims. Companies must decide whether to design the product as a primary-protection sunscreen (with the full regulatory and labeling burden this entails) or as a multifunctional product that offers incidental protection without primary sunscreen claims.

SPF claim testing To label a product with an SPF number, in vivo SPF testing compliant with regulatory protocol is generally required. Even when a product is intended to offer incidental protection, over-claiming can trigger enforcement. Brands must ensure test methods, application rates (mg/cm^2), and consumer messaging align. A daily moisturizer that delivers SPF 15 under lab application conditions may deliver much lower protection under real-world application amounts; that discrepancy must be managed in claims and consumer education.

Broad-spectrum and UVA labeling Regulatory frameworks differ in how they define and permit "broad spectrum." For example, Canada and the U.S. (if and when bemotrizinol is included in the monograph) require demonstration of UVA protection, often quantified by critical wavelength and persistent pigment darkening (PPD) measures. If brands want to claim “broad spectrum” on pack, they must have the appropriate test data to substantiate that claim.

Ingredient listing and INCI Bemotrizinol should appear in ingredient lists with its INCI name (bemotrizinol or PARSOL Shield where permitted); transparency supports regulatory compliance and consumer trust. Some jurisdictions also require filter concentration disclosures; brands must prepare label text accordingly.

Marketing and consumer messaging Products with incidental SPF should emphasize consistent daily use while remaining honest about what level of sun protection consumers can expect from routine application patterns. Brands that choose not to make primary sunscreen claims should still educate customers on reapplication cadence, layering considerations (e.g., applying a dedicated sunscreen when extended sun exposure is expected), and how product application affects protection.

Legal and regulatory counsel Given the complexity of cross-border rules, brands should engage regulatory counsel when defining claims and launch strategies. Misclassifying a product or making unsupported SPF claims creates legal and reputational risk.

Risks, unknowns and quality control

The pathway to broader use of bemotrizinol is evidence-based, but risks remain that companies must manage through rigorous testing and quality systems.

Application-consistent protection Laboratory SPF results often assume uniform application at 2 mg/cm^2, a quantity consumers rarely achieve with leave-on skincare or makeup. Real-world protection can be lower. Brands should test for real-use application patterns and use conservative claim language or deliver consumer education to address this behavior gap.

Supply chain and ingredient stewardship Increased demand for bemotrizinol could put pressure on suppliers, creating potential bottlenecks or variability. Brands must qualify multiple suppliers and implement incoming quality controls to ensure consistent purity and performance.

Photodegradation under complex matrices Although bemotrizinol is photostable, interactions with novel actives, pigments, or packaging-related photochemical dynamics can create unexpected degradation pathways. Stability testing under intended packaging conditions (opaque vs clear) and accelerated light exposure is essential.

Regulatory divergence and enforcement Countries maintain different rules for what constitutes a sunscreen vs a cosmetic. A multifunctional product permissible in Canada may face stricter classification in another market. Brands must map regulatory requirements across all target markets and design strategies that factor in enforcement complexity.

Business implications and market outlook

The Canadian allowance accelerates a trend already visible in markets outside North America: consumers expect daily protection integrated into their beauty routines. Brands positioned to deliver effective, elegant SPF solutions within everyday SKUs stand to capture incremental spend from users who prioritize convenience and texture.

Competitive dynamics Companies that can reformulate existing best-sellers quickly to include bemotrizinol at permissible levels may gain first-mover advantage. Larger multinationals with global regulatory teams and manufacturing scale will be best placed to operationalize a global chassis approach. Niche and indie brands can still differentiate through unique actives, positioning, or superior sensory experiences; the inclusion of bemotrizinol simply lowers the technical barrier.

Public health potential Embedding reliable protection into widely used day products could increase routine photoprotection uptake. The public health benefit depends on product efficacy in real-world use and consumer adherence. When a moisturizer or foundation yields meaningful UVB and UVA blockade, it reduces cumulative exposure over time — a factor highly relevant to photoaging and skin cancer prevention strategies.

Market segmentation and pricing Inclusion of high-performing filters often increases ingredient costs. Brands must balance price sensitivity with claims value. Premiumization strategies can commercialize the protection benefit, while mid-market brands can pursue optimizations that keep price points competitive.

Steps brands and formulators should take now

For teams ready to act on Health Canada’s change, a practical checklist will accelerate safe and compliant product development:

1. Audit current portfolios for suitable SKUs that could benefit from bemotrizinol inclusion without compromising brand identity.
2. Engage suppliers early to secure bemotrizinol supply and technical data packs, including certificates of analysis and stability information.
3. Run lab-scale proof-of-concept formulations testing filter synergy, photostability, and sensory attributes.
4. Conduct in vitro and in vivo SPF/UVA tests on finished formulations intended to carry SPF claims; for multifunctional claims, evaluate real-world application scenarios.
5. Implement full stability and compatibility testing across actives, pigments, packaging and storage conditions.
6. Coordinate regulatory review to define whether each SKU will be marketed as a primary sunscreen or as a multifunctional product with secondary protection; prepare labeling and claims accordingly.
7. Plan consumer education and usage guidance to bridge the gap between lab-tested application rates and typical consumer habits.
8. Prepare post-market surveillance and quality control processes to monitor field performance and adverse event reporting.

This pragmatic approach mitigates risk while enabling faster adoption of the ingredient into consumer-ready products.

What the updated monograph suggests about future regulatory trends

Health Canada’s move reflects a broader, incremental harmonization across major markets. Regulators increasingly evaluate filters on a dataset-driven basis rather than defaulting to historical listings. When safety and performance data are robust, authorities are more willing to expand allowable uses in ways that acknowledge consumer behavior and market demand.

The trend favors ingredients with long real-world use histories and comprehensive safety dossiers. Industry can expect regulators to continue prioritizing photostability, systemic exposure metrics, and real-world performance endpoints when reviewing novel filters or expanded uses. For brands, the implication is clear: invest in high-quality, reproducible data packages and cross-jurisdictional dossiers to accelerate market access.

Final considerations for marketers and consumer-facing teams

Product developers and regulatory teams must coordinate tightly with marketing to ensure on-pack language reflects regulatory status and consumer benefits without overpromising. Marketing should emphasize tangible benefits—lightweight feel, no white cast, daily wearable protection—while ensuring the claims are substantiated by tests aligned with regulatory expectations.

Consumer trust will hinge on transparency. Including concise educational copy about the nature of incidental protection and recommended use patterns will reduce confusion. Where products provide meaningful SPF under test conditions, consider adding clear guidance for real-world application and reapplication to help consumers achieve the protection they expect.

Health Canada’s decision creates room for innovation without replacing the functional need for dedicated sunscreens in high-exposure situations. Positioning multifunctional SKUs as part of a prevention-oriented routine rather than a substitute for dedicated sun-care will align marketing with sound public health messaging.

FAQ

Q: What exactly did Health Canada change with bemotrizinol? A: Health Canada added bemotrizinol (PARSOL Shield) to the Secondary Sunscreen Monograph, allowing its use in multifunctional topical products (such as daily skincare and color cosmetics) with a concentration limit of up to 6%. The update also removed a previous footnote restricting certain formulation parameters, giving formulators more flexibility.

Q: Does this mean any cosmetic can claim SPF in Canada now? A: No. Products that are marketed primarily as sunscreens and make direct SPF claims must comply with the Primary Sunscreen Monograph requirements and undergo the necessary testing and labeling protocols. The Secondary Monograph allows bemotrizinol to be included in products where sun protection is not the primary purpose, but brands must carefully manage claims and labeling consistent with regulatory rules.

Q: Will this speed up U.S. approval of bemotrizinol? A: The Canadian decision strengthens the global evidence base and regulatory momentum for bemotrizinol, which can help the FDA’s ongoing review. Industry sources expect a potential final order under the FDA’s Tier 1 OMOR process by June 2026, with the rule effective 60 days later, but the final U.S. decision remains subject to the FDA’s assessment.

Q: How does bemotrizinol differ from other UV filters? A: Bemotrizinol is prized for its photostability, broad-spectrum coverage at relatively low concentrations, and compatibility with both organic and inorganic filters as well as oils and active ingredients. These properties support lighter textures, reduced whitening, and product formats that preserve shade integrity in color cosmetics.

Q: If I’m a formulator, what testing should I run for products containing bemotrizinol? A: Perform photostability testing and confirm final SPF and UVA performance via appropriate in vitro and in vivo methods. Conduct stability testing across intended packaging and storage conditions, pigment compatibility studies for colored products, and interaction tests with active ingredients. If making SPF claims, comply with regional in vivo SPF testing standards and labeling requirements.

Q: Will adding bemotrizinol make products more expensive? A: High-performing filters typically increase raw material costs, but the overall cost impact depends on formulation design, concentration used, and supply-chain factors. The ability to use a single efficient filter at lower concentrations and to reduce SKU proliferation can offset some cost increases.

Q: Does bemotrizinol present any known environmental concerns? A: Health Canada’s decision was based on human safety and performance data; environmental assessments vary by jurisdiction and are considered separately. Brands should review both human safety and any available environmental impact data when planning product portfolios and supply chains.

Q: How should brands communicate protection benefits to consumers? A: Be transparent about the level of protection (and testing behind any SPF claims). For multifunctional products that are not marketed as primary sunscreens, provide usage guidance and recommend a dedicated sunscreen for prolonged or intense sun exposure. Educate consumers about realistic application amounts to help them achieve expected protection.

Q: Are there immediate product examples consumers can expect? A: Expect to see reformulated daily moisturizers, tinted serums, foundations and BB/CC creams designed to deliver incidental but substantive UV protection with minimal whitening and refined textures. Brands that move quickly will target formulations where texture and shade fidelity are critical.

Q: What should manufacturers do next? A: Secure supply and technical documentation for bemotrizinol, run formulation and stability trials, plan regulatory labeling strategies for each target market, and prepare consumer education materials. Coordinate across R&D, regulatory, manufacturing and marketing teams to ensure claims, performance and messaging align.